title: Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.
abstract: 1. This study examined the pharmacokinetics, distribution, metabolism and excretion of the selective prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-33679). The compounds were investigated following oral and/or intravenous administration to intact rats, dogs and monkeys, and bile-duct-cannulated rats and dogs. 2. After oral administration of [14C]selexipag, selexipag was well absorbed in rats and dogs with total recoveries of over 90% of the dose, mainly in the faeces. Biliary excretion was the major elimination pathway for [14C]MRE-269 as well as [14C]selexipag, while renal elimination was of little importance. [14C]Selexipag-related radioactivity was secreted into the milk in lactating rats. 3. Plasma was analysed for total radioactivity, selexipag and MRE-269 in rats and monkeys. Selexipag was negligible in rat plasma due to extensive metabolism, and MRE-269 was present in rat and monkey plasma. A species difference was clearly evident when selexipag was incubated in rat, dog and monkey plasma. 4. Total radioactivity was rapidly distributed to tissues. The highest concentrations were found in the bile duct and liver without significant accumulation or persistence, while there was limited melanin-associated binding, penetration of the blood-brain barrier and placental transfer of drug-related materials.
authors.affiliation: a Pharmacokinetics and Safety Assessment Department, Nippon Shinyaku Co., Ltd , Kyoto , Japan and.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ichikawa
authors.affiliation: a Pharmacokinetics and Safety Assessment Department, Nippon Shinyaku Co., Ltd , Kyoto , Japan and.
authors.forename: Tetsuhiro
authors.initials: T
authors.lastname: Yamada
authors.affiliation: b Preclinical Pharmacokinetics and Metabolism, Actelion Pharmaceuticals Ltd , Allschwil , Switzerland.
authors.forename: Alexander
authors.initials: A
authors.lastname: Treiber
authors.affiliation: b Preclinical Pharmacokinetics and Metabolism, Actelion Pharmaceuticals Ltd , Allschwil , Switzerland.
authors.forename: Carmela
authors.initials: C
authors.lastname: Gnerre
authors.affiliation: a Pharmacokinetics and Safety Assessment Department, Nippon Shinyaku Co., Ltd , Kyoto , Japan and.
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Nonaka
mesh_terms: D000081:Acetamides / Q000493:pharmacokinetics*; D000818:Animals; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D004285:Dogs; D007408:Intestinal Absorption; D008252:Macaca fascicularis; D011719:Pyrazines / Q000493:pharmacokinetics*; D051381:Rats; D044006:Receptors, Epoprostenol / Q000819:agonists; D013045:Species Specificity; D014018:Tissue Distribution
chemical_list: D000081:Acetamides; D000959:Antihypertensive Agents; D011719:Pyrazines; D044006:Receptors, Epoprostenol; C523468:selexipag
keywords: Distribution; excretion; hydrolysis; mass balance; pharmacokinetics; prostacyclin receptor agonist; selexipag